Virax Biolabs Group Ltd (NASDAQ:VRAX) price on current trading day, fall -1.52% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $2.59.
A look at the stock’s price movement, the close in the last trading session was $2.63, moving within a range at $2.4 and $2.66. The beta value (5-Year monthly) was 2.051. Turning to its 52-week performance, $9.00 and $0.60 were the 52-week high and 52-week low respectively. Overall, VRAX moved 49.71% over the past month.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Virax Biolabs Group Ltd’s market cap currently stands at around $11.24 million, with investors looking forward to this quarter’s earnings report slated for in October.
Turning to the stock’s technical picture we see that short term indicators suggest on average that VRAX is a 50% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
VRAX’s current price about -36.21% and 10.72% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 43.57, while 7-day volatility ratio is 11.49% and 30.80% in the 30-day chart. Further, Virax Biolabs Group Ltd (VRAX) has a beta value of 2.22, and an average true range (ATR) of 0.81.
If we refocus on Virax Biolabs Group Ltd (NASDAQ:VRAX), historical trading data shows that trading volumes averaged 1.7 over the past 10 days and 4.36 million over the past 3 months. The company’s latest data on shares outstanding shows there are 4.34 million shares.
The 6.63% of Virax Biolabs Group Ltd’s shares are in the hands of company insiders while institutional holders own 1.63% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 0.63 million on 2024-08-30, giving us a short ratio of 0.06. The data shows that as of 2024-08-30 short interest in Virax Biolabs Group Ltd (VRAX) stood at 1560.0 of shares outstanding, with shares short rising to 18866.0 registered in 2024-07-31. Current price change has pushed the stock 77.40% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VRAX stock continues to rise going into the next quarter.
